Bevacizumab Biosimilar Plus FOLFOX4 in the Treatment of Recurrent HCC After Liver Transplantation
Status:
Not yet recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This study is a single arm, single center, prospective and open exploratory study.
About 15 patients with recurrent hepatocellular carcinoma (HCC) after liver transplantation
are expected to be enrolled.Patients will be treated with bevacizumab and FOLFOX4.Treatment
was continued until disease progression, development of intolerable toxicities, death,
withdrawal of consent, initiation of new antitumor therapy, whichever occurred first.
Phase:
Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University